Tier 2 — strong

Effects of quercetin supplementation on inflammatory factors and quality of life in post-myocardial infarction patients: A double blind, placebo-controlled, randomized clinical trial

Fereshteh Dehghani, Seyed Hashem Sezavar Seyedi Jandaghi, Leila Janani, Mohammadtaghi Sarebanhassanabadi, Hadi Emamat, Mohammadreza Vafa
Phytotherapy research : PTR 2021 35(4):2085-2098

Bibliography

PubMed
PMID 33216421
DOI
10.1002/ptr.6955
Funding
Indexed grant support: 32039 — Iran University of Medical Sciences. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample88 adults following myocardial infarction; 44 per group
InterventionQuercetin 500 mg/day versus placebo
Duration8 weeks
EndpointsBlood pressure; Inflammatory measures; Oxidative-stress measures

What the study showed, in plain terms

Published in 2021, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 88 adults following myocardial infarction; 44 per group. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 8 weeks.

Total antioxidant capacity and one quality-of-life dimension improved. Inflammatory markers and blood pressure did not improve versus placebo.

Multiple endpoints and a short follow-up. The later endothelial/depression report shares this registered trial.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Total antioxidant capacity and one quality-of-life dimension improved.
  • Inflammatory markers and blood pressure did not improve versus placebo.
  • The recorded outcome domains were Blood pressure; Inflammatory measures; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 8 weeks.

What this study can and cannot tell us

  • Multiple endpoints and a short follow-up. The later endothelial/depression report shares this registered trial.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of quercetin supplementation on endothelial dysfunction biomarkers and depression in post-myocardial infarction patients: A double-blind, placebo-controlled, randomized clinical trial
Fereshteh Dehghani et al. · Clinical nutrition ESPEN · 2023
Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology